# Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

> **NCT03297606** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 720 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Advanced Solid Tumors

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Dasatinib
- **DRUG:** Nivolumab plus Ipilimumab
- **DRUG:** Axitinib
- **DRUG:** Bosutinib
- **DRUG:** Crizotinib
- **DRUG:** Palbociclib
- **DRUG:** Sunitinib
- **DRUG:** Temsirolimus
- **DRUG:** Erlotinib
- **DRUG:** Trastuzumab plus Pertuzumab
- **DRUG:** Vemurafenib plus Cobimetinib
- **DRUG:** Vismodegib
- **DRUG:** Tucatinib

## Key facts

- **NCT ID:** NCT03297606
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-03-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03297606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03297606, "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03297606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*